Richard Herrmann

14.1k total citations · 4 hit papers
215 papers, 10.0k citations indexed

About

Richard Herrmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Richard Herrmann has authored 215 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 46 papers in Hematology. Recurrent topics in Richard Herrmann's work include Colorectal Cancer Treatments and Studies (30 papers), Lymphoma Diagnosis and Treatment (24 papers) and Lung Cancer Treatments and Mutations (23 papers). Richard Herrmann is often cited by papers focused on Colorectal Cancer Treatments and Studies (30 papers), Lymphoma Diagnosis and Treatment (24 papers) and Lung Cancer Treatments and Mutations (23 papers). Richard Herrmann collaborates with scholars based in Switzerland, Australia and Germany. Richard Herrmann's co-authors include Christoph Rochlitz, Andrew Grigg, Chris Arthur, Timothy P. Hughes, Kerry Taylor, Zbigniew Rudzki, Kevin Lynch, Susan Branford, M. Stern and Werner Scheithauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Richard Herrmann

209 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

2009 602 citations Werner Scheithauer, Richard Herrmann et al. profile →
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

2003 561 citations Jeff Szer, Richard Herrmann et al. Blood profile →
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

2003 538 citations Richard Herrmann et al. profile →
High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

2002 517 citations Richard Herrmann et al. Blood profile →

Peers

Countries citing papers authored by Richard Herrmann

Since Specialization

Citations

This map shows the geographic impact of Richard Herrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Herrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Herrmann more than expected).

Fields of papers citing papers by Richard Herrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Herrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Herrmann. The network helps show where Richard Herrmann may publish in the future.

Co-authorship network of co-authors of Richard Herrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Herrmann. A scholar is included among the top collaborators of Richard Herrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Herrmann. Richard Herrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) 2015 ·Annals of Oncology ·Dieter Koeberle, Daniel Betticher, Roger von Moos, D. Dietrich, Peter Brauchli, (unknown), (unknown), Sun Young Rha, Markus Borner, Sandro Anchisi, Peter Moosmann, Attila Kollár, Piercarlo Saletti, A. Roth, M. Frueh, (unknown), Răzvan Popescu, (unknown), Viviane Hess, Richard Herrmann	92
2	Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study 2014 ·BMC Cancer ·Benjamin Kasenda, (unknown), Dieter Koeberle, Bernhard C. Pestalozzi, Markus Borner, Richard Herrmann, Lorenz Jost, Andreas Lohri, Viviane Hess	37
3	Clinical Benefit Response in Pancreatic Cancer Trials Revisited 2014 ·Oncology Research and Treatment ·Jürg Bernhard, Daniel Dietrich, Bengt Glimelius, G. Bodoky, Werner Scheithauer, Richard Herrmann	9
4	A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy 2013 ·Clinical Gastroenterology and Hepatology ·Geoffrey M Forbes, Marian Sturm, Rupert W. Leong, Miles Sparrow, Dev Segarajasingam, Adrian G. Cummins, Michael Phillips, Richard Herrmann	260
5	Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth 2011 ·Clinical Cancer Research ·Andreas Wicki, Christoph Rochlitz, Annette Orleth, Reto Ritschard, Imke Albrecht, Richard Herrmann, Gerhard Christofori, Christoph Mamot	77
6	A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies 2010 ·Acta Oncologica ·Elisa Gallerani, Jean Bauer, Dagmar Hess, (unknown), (unknown), (unknown), (unknown), Richard Herrmann, Silvia Marsoni, (unknown), Cristiana Sessa	11
7	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial 2008 ·BMC Cancer ·Jorge Sierra, Jeff Szer, Jeannine Kassis, Richard Herrmann, Mario Lazzarino, Xavier Thomas, Stephen J. Noga, Nigel Baker, Roger Dansey, Alberto Bosi	40
8	Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia 2007 ·Biology of Blood and Marrow Transplantation ·John J. Moore, Ian Nivison‐Smith, Kim‐Leng Goh, Dávid Ma, Ken Bradstock, Jeff Szer, Simon Durrant, Anthony P. Schwarer, Peter Bardy, Richard Herrmann, Anthony J. Dodds	70
9	Quantitative Determination of JAK2 V617F by TaqMan 2007 ·Journal of Molecular Diagnostics ·E. Hammond, Kathryn Shaw, (unknown), (unknown), Ian James, Richard Herrmann	23
10	Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial 2004 ·Lung Cancer ·Miklos Pless, Christian Waldherr, Helmut R. Maëcke, Carlos Buitrago, Richard Herrmann, Jan Mueller‐Brand	28
11	STRAP Is a Strong Predictive Marker of Adjuvant Chemotherapy Benefit in Colorectal Cancer 2004 ·Neoplasia ·Martin Buess, Luigi Terracciano, (unknown), Pierluigi Ballabeni, Jean‐Louis Boulay, U Laffer, U Metzger, Richard Herrmann, Christoph Rochlitz	25
12	Amplification of SKI Is a Prognostic Marker in Early Colorectal Cancer 2004 ·Neoplasia ·Martin Buess, Luigi Terracciano, (unknown), Pierluigi Ballabeni, Jean‐Louis Boulay, U Laffer, U Metzger, Richard Herrmann, Christoph Rochlitz	54
13	Toxic Encephalopathy Induced by Capecitabine 2004 ·Oncology ·Bernd Niemann, (unknown), Richard Herrmann, Miklos Pless	36
14	Single dose per cycle pegfilgrastim successfully supports full dose intensity CHOP-14 in patients over 60 years with non-Hodgkin's lymphoma (NHL) and successfully mobilises peripheral blood progenitor cells (PBPC). 2003 ·Blood ·Michael A. Bentley, Paula Marlton, N. Horvath, (unknown), (unknown), Richard Herrmann, Christopher Arthur, Simon Durrant, (unknown), (unknown), (unknown), (unknown)	5
15	Impact of Overall Treatment Time on Local Control of Anal Cancer Treated with Radiochemotherapy 2003 ·Oncology ·R. Graf, Peter Wust, Bert Hildebrandt, (unknown), Reiner Ullrich, Richard Herrmann, Hanno Riess, (unknown)	79
16	Maligner Verlauf einer pigmentierten villonodulären Synovialitis der Beugesehnenscheide des Kleinfingers - Fallbericht und Literaturübersicht* 2000 ·Handchirurgie · Mikrochirurgie · Plastische Chirurgie ·(unknown), Hanno Troeger, (unknown), Gernot Jundt, (unknown), Richard Herrmann, (unknown)	6
17	Quality of life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy 1999 ·Annals of Oncology ·J. Bernhard, Christoph Hürny, Rudolf Maibach, Richard Herrmann, U Laffer	103
18	4′-lodo-4′-Deoxydoxorubicin (IDX) in Colorectal Cancer – A Multicenter Phase II Study 1995 ·Oncology Research and Treatment ·Richard Herrmann, K. Mross, Ulrich R. Kleeberg, E.D. Kreuser, R. Becher, Lutz Edler, W. Queißer, P. Liati, S. Kerpel‐Fronius	1
19	A prospective study of screening upper gastrointestinal (GI) endoscopy prior to and after bone marrow transplantation (BMT) 1995 ·Australian and New Zealand Journal of Medicine ·Geoffrey M Forbes, Simon Rule, Richard Herrmann, J. M. Davies, Brendan Collins	3
20	Liver disease complicating bone marrow transplantation: A clinical audit 1995 ·Journal of Gastroenterology and Hepatology ·Geoffrey M Forbes, John Davies, Richard Herrmann, Brendan Collins	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact